Actinium Pharmaceuticals, Inc. Goes Public via a Reverse Merger into Cactus Ventures, Inc.

 Actinium Pharmaceuticals, Inc. Goes Public via a Reverse Merger into Cactus
                                Ventures, Inc.

PR Newswire

NEW YORK, Jan. 3, 2013

NEW YORK, Jan.3, 2013 /PRNewswire/ --Actinium Pharmaceuticals, Inc.
("Actinium") announced today that it went public via a reverse merger into
Cactus Ventures, Inc. (OTCBB: CTVN), a fully reporting public company (the
"Company") pursuant to a share exchange agreement dated December 28, 2012. As
a result of the share exchange, former shareholders of Actinium became the
controlling shareholders of the public Company. On the closing of the share
exchange approximately 21% of Actinium's issued and outstanding shares were
exchanged for 4,309,015 shares of the Company's common stock. The Company's
stock will trade under the name Cactus Ventures, Inc. until such time as the
intended name change to Actinium Pharmaceuticals, Inc. takes effect. 

The Company will continue to exchange its shares of common stock for shares of
Actinium held by the remaining Actinium shareholders and urges existing
Actinium shareholders to do so as quickly as possible.

Jack Talley, our President and Chief Executive Officer, said: "As we are
expanding our ongoing clinical trials and adding new ones, it is very
important to have access to public markets and provide liquidity for our
investors who helped us reach this stage in the clinical development of our
drug candidates."

Mr. Talley will serve as our President and Chief Executive Officer of the
newly public company. Dragan Cicic, MD will serve as our Chief Operating
Officer and Chief Medical Officer. Enza Guagenti will serve as our Chief
Financial Officer. Our Board of Directors will include Mr. Talley, Dr.
Rosemary Mazanet, David Nicholson, Sandesh Seth and Sergio Traversa. The
Company will be based in New York, NY.

On December 26, 2012, Actinium announced that it completed a first closing of
$5.1 million in its current round of financing (the "Offering"), for which
Laidlaw & Company (UK) Ltd. is the exclusive placement agent. Funding from the
Offering will be used primarily for further development of Actimab™A,
Actinium's lead drug candidate in multicenter Phase I/II trials in Acute
Myeloid Leukemia (AML) and Iomab™ – B, a Phase II clinical stage bone marrow
conditioning agent for preparing patients for hematopoietic stem cell

Post the closing of the share exchange, the Company will continue the Offering
on the same terms on a pro-forma basis with the common shares offered at $1.65
per share, the 120 day warrants exercise price at $1.65 per share and the 5
year warrants exercise price at $2.47 per share. Investors in the Offering
will receive securities of the Company, the public company, and not Actinium.
The Company is authorized to sell up to $15 million in gross proceeds in the

More information about the transaction may be found in a current report on
Form 8-K filed on January 2, 2013 with the United States Securities and
Exchange Commission.

This press release shall not constitute an offer to sell or the solicitation
of an offer to participate in the Offering. This press release is being issued
pursuant to and in accordance with Rule 135 under the Securities Act of 1933,
as amended.

About the Company

The Company is a New York, New York based biopharmaceutical company that
develops innovative alpha particle immunotherapeutics based on its proprietary
platform for the therapeutic utilization of alpha particle emitting
actinium-225 and bismuth-213 isotopes in association with monoclonal
antibodies. The Company also develops other radiopharmaceuticals for select

Forward-Looking Statements

This press release contains forward-looking statements as defined within
Section 27A of the Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. These statements relate to future
events, including our ability to raise capital, and to our future financial
performance, and involve known and unknown risks, uncertainties and other
factors that may cause our actual results, levels of activity, performance, or
achievements to be materially different from any future results, levels of
activity, performance or achievements expressed or implied by these
forward-looking statements. These forward-looking statements are based on
current expectations, estimates and projections about the Company's industry,
management's beliefs and certain assumptions made by management. You should
not place undue reliance on forward-looking statements since they involve
known and unknown risks, uncertainties and other factors which are, in some
cases, beyond our control and which could, and likely will, materially affect
actual results, levels of activity, performance or achievements. Any
forward-looking statement reflects our current views with respect to future
events and is subject to these and other risks, uncertainties and assumptions
relating to our operations, results of operations, growth strategy and
liquidity. We assume no obligation to publicly update or revise these
forward-looking statements for any reason, or to update the reasons actual
results could differ materially from those anticipated in these
forward-looking statements, even if new information becomes available in the
future. Additional information concerning certain risks and uncertainties that
could cause actual results to differ materially from that projected or
suggested is contained in the Company's filings with the Securities and
Exchange Commission (SEC), copies of which are available from the SEC or may
be obtained upon request from the Company.
For more information:

Visit our web site  or contact:

Dennis S. Dobson Jr., 203-258-0159

Jack Talley, CEO
Actinium Pharmaceuticals Inc.
Tel: (646) 459-4201

Jeff Ramson
ProActive Capital Group, LLC
Tel: (646) 863-6341

SOURCE Actinium Pharmaceuticals, Inc.

Press spacebar to pause and continue. Press esc to stop.